Insulin rapidly stimulates tyrosine kinase activity of its receptor resulting in phosphorylation of its cytosolic substrate, insulin receptor substrate-i (IRS-1), which in turn associates with phosphatidylinositol 3-kinase (PI 3-kinase), thus activating the enzyme. Glucocorticoid treatment is known to produce insulin resistance, but the exact molecular mechanism is unknown. In the present study we have examined the levels and phosphorylation state of the insulin receptor and IRS-1, as well as the association/activation between IRS-1 and PI 3-kinase in the liver and muscle of rats treated with dexamethasone.
Introduction
Insulin initiates its metabolic and growth-promoting effects by binding to the a subunit of its tetrameric receptor, thereby activating the tyrosine kinase in the ,B subunit ( 1, 2) . This catalyzes the intramolecular autophosphorylation of specific tyrosine residues of the ,B subunit further enhancing the tyrosine kinase of the receptor toward other protein substrates (3) . In most cells, this primary event leads to the subsequent tyrosyl phosphorylation ofa cytoplasmic protein with an apparent molecular mass between 160 and 185 kD called insulin receptor substrate 1 (IRS-1 )' (3) (4) (5) . Considerable evidence demonstrates that insulin receptor tyrosine kinase activity and associated IRS-1 phosphorylation are essential for many, if not all, of the biological effects of insulin ( 1, 6, 7) . In cells in culture and in vitro, phosphorylated IRS-1 associates with the lipid metabolizing enzyme phosphatidylinositol 3-kinase (PI 3-kinase) resulting in activation of the enzyme (8) . Recently, our laboratory has demonstrated that insulin is capable ofstimulating PI 3-kinase activity in liver and muscle ofthe intact animal under physiological conditions and that IRS-l phosphorylation may play a significant role in the association/activation with PI-3-kinase in vivo (9) . Thus, the insulin receptor, IRS-1 and PI-3-kinase represent three of the earliest steps in insulin action, and each of these can be demonstrated in two of the main target tissues for the metabolic actions of insulin in vivo, liver and muscle.
It has long been known that glucocorticoid excess causes insulin resistance (10) (11) (12) (13) (14) (15) . Hypercortisolemia is associated with increased glucose production by the liver (10) , decreased peripheral glucose transport and utilization ( 1 1, 13), decreased protein synthesis, and increased protein degradation in muscle ( 16) . The mechanisms by which glucocorticoids exert these effects are unknown. Changes in binding ofinsulin to its receptor after glucocorticoid treatment have been observed, but do not appear to account for the insulin resistance ( 12) . Using purified receptors and artificial substrates in vitro, decreased insulin receptor phosphorylation and kinase activity have been reported to occur in the liver but not in the muscle ofdexameth-asone-treated animals (17, 18) . Using anti-IRS-I and antiphosphotyrosine antibodies, we recently showed that reduced IRS-I phosphorylation may have an important role in another state of insulin resistance, the ob/ob mouse model of type II diabetes mellitus ( 19) . The role ofthe expression or phosphorylation of the endogenous substrate for the insulin receptor, IRS-1, and its association/activation with PI 3-kinase in vivo have not been examined in insulin resistance induced by glucocorticoids. In the present study, we have examined the phosphorylation state of the insulin receptor and IRS-1 and the activation of PI 3-kinase after insulin stimulation in vivo, as well as the levels of these three proteins in liver and muscle of dexamethasone-treated rats.
Methods

Materials
Reagents for SDS-PAGE and immunoblotting were from Bio-Rad Laboratories (Richmond, CA (20) . Anti-IRS-I antibodies were raised in rabbits using a synthetic peptide (Pep 80) derived from the amino acid sequence (YIP-GATMGTSPALTGDEAA) corresponding to residues 489-507 ofthe rat protein and affinity purified on a column prepared by coupling the synthetic peptide to Affi-Gel 10 (Bio-Rad Laboratories) as previously described (4) . Anti-rat-PI 3-kinase antiserum was from UBI (Lake Placid, NY). Antiinsulin receptor antibody was raised in rabbits using a synthetic peptide derived from the amino acid sequence (KKNGRILTLPRSNPS) corresponding to the C terminus of the rat protein.
Methods
Animals and tissue extracts. Male rats ( 1 30-180 g) were allowed access to standard rodent chow and water ad libitum. Rats were injected daily at -10:00 a.m. with 1 mg/kg dexamethasone or an equal volume of saline (control group) for 5 d. Food was withdrawn 12-14 h before experiments, and studies were performed in parallel for the control and treated rats in each pair.
Rats were anesthetized with sodium amobarbital (15 mg/kg body wt intraperitoneally) and used in experiments 10-15 min later, as soon as anesthesia was assured by loss of pedal and corneal reflexes. The abdominal cavity was opened, the portal vein exposed, and 1 ml of normal saline (0.9% NaCi) with or without i0-5 M insulin was injected. This is equivalent to injection of 60 jig ofinsulin or -1.5 U per animal. At In preliminary experiments, we showed that the maximal phosphorylation ofIRS-I occurs between 30 and 60 s in liver and between 1 and 4 min in muscle after intraportal insulin infusion. Using a 1-ml vol, the concentrations of insulin that give maximal stimulation were 10-6 and I0-5 M insulin for liver and muscle, respectively. For these experiments, we infused I0-5 M insulin and extracted liver at 30 s and muscle at 1.5 min, thus sampling at the peak of phosphorylation events. Dose-response studies of insulin receptor phosphorylation, IRS-I phosphorylation, and IRS-I -associated PI 3-kinase activity after intraportal infusion in the intact rat show that half-maximal stimulation occurs at physiological postprandial concentration (9) . In some experiments, the livers were extracted in a identical way as muscle, and the supernatant solutions of the muscle and livers were used for immunoprecipitation with anti-IRS-I antibody. Protein analysis by immunoblotting. The samples were treated with Laemmli sample buffer (21 ) with 100 mM DTT and heated in a boiling water bath for 4 min. For total extracts, similar size aliquots of sample ( 150 ,ug ofprotein) were subjected to SDS-PAGE (6% tris acrylamide) in a miniature slab gel apparatus (Bio-Rad Laboratories). Electrotransfer of proteins from the gel to nitrocellulose was performed for 1 h at 90 V (constant) in the miniature transfer apparatus (Mini-Protean; Bio-Rad Laboratories) as described by Towbin et al. (22) but with 0.02% SDS added to the transfer buffer to enhance elution ofhigh molecular mass proteins. Nonspecific protein binding to the nitrocellulose was reduced by preincubating the filter overnight at 4VC in blocking buffer (3% BSA, 10 mM Tris (pH 7.5), 150 mM NaCl, and 0.02% Tween 20). Prestained molecular weight standards were myosin (205 kD), 3-galactosidase (1 16 kD), bovine serum albumin (80 kD), and ovalbumin (49.5 kD).
The nitrocellulose blot was incubated with antiphosphotyrosine antibodies (apY, 0.3 jg/ml) or with anti-IRS-1 antibodies (0.3 jg/ml ap8O) diluted in blocking buffer for 4 h at 22°C and washed for 60 min with the blocking buffer without BSA. The blots were then incubated with 2 jCi of '25I-protein A (30 jCi/jig) in 10 ml ofblocking buffer for 1 h at 22°C and washed again as described above for 2 h. I25I-protein A bound to the antiphosphotyrosine and anti-IRS-I antibodies was detected by autoradiography using preflashed Kodak XAR film with Cronex Lightning Plus intensifying screens at -70°C for 12-48 h. Band intensities were quantitated by optical densitometry (Molecular Dynamics, Sunnyvale, CA) of the developed autoradiogram.
Phosphatidylinositol 3-kinase activity. PI 3-kinase activity was measured by in vitro phosphorylation ofphosphatidylinositol as previously described (9, 23). After insulin injection into the portal vein, a portion of the left lobe of liver and the hindlimb skeletal muscle were removed and homogenized immediately in (1 / 10 wt/vol) ice-cold solubilization buffer (buffer C) with a Polytron PTA 20S generator (model PT 10/35; Brinkmann Instruments) operated at maximum speed for 30 s and left to sit on ice for 30 min. The solubilization buffer C was composed of 50 mM Hepes (pH 7.5), 137 mM NaCl, 1 mM MgCl2, 1 mM CaCI2, 2 mM Na3VO4, 10 mM sodium pyrophosphate, 10 mM sodium fluoride, 2 mM EDTA, 1% NP-40, 10% glycerol, 2 jig/ml aprotinin, 10 ,jg/ml antipain, 5 ug/ml leupeptin, 0.5 jig/ml pepstatin, 1.5 mg/ml benzamidine, and 34 ,jg/ml PMSF. Insoluble material was removed by centrifugation at 15,000 rpm in a rotor (model 7OTi; Beckman Instruments, Inc.) for 50 min. IRS-I was immunoprecipitated from aliquots of the supernatant containing 12 mg protein with anti-IRS-I (0.3 jg/mil apep8O) or preimmune rabbit IgG (0.3 jig/ml) followed by protein A-Sepharose 6MB. The immunoprecipitates were washed successively in PBS containing 1% NP-40 and 100 AM Na3VO4 (three times), 100 mM Tris (pH 7.5) containing 500 mM LiC12, and 100 AM Na3VO4 (three times), and 10 mM Tris (pH 7.5) containing 100 mM NaCl, 1 mM EDTA, and 100 AM Na3VO4 (two times). The pellets were resuspended in 50 A1 of 10 mM Tris (pH 7.5) containing 100 mM NaCl and 1 mM EDTA. 10 
Statistics
Experiments were always performed studying samples from the dexamethasone-treated animals in parallel with a control group. Comparisons were made using paired and unpaired t tests as appropriate. The level of significance used was P < 0.05.
Results
Characteristics ofdexamethasone-treated rats. 139±4 277±18 (6) 78±15 (6) The data are represented as the mean±SEM. into portal vein as a bolus injection, and 90 s later, muscles were excised and homogenized in extraction buffer B at 4VC as described in Methods. After centrifugation, aliquots with same amount of protein were resolved on 6% SDS-polyacrylamide gel, transferred to nitrocellulose, and detected with antiphosphotyrosine antibody (A), anti-IRS-1 antibody (B), or antiinsulin receptor antibody (C), and 1251_
protein A, and subjected to autoradiography. Dex, dexamethasone.
Effect of dexamethasone on insulin receptor and IRS-I phosphorylation in muscle ofrats. Fig. 1 illustrates the protocol for assessment of insulin receptor signaling in the intact rat. Control and dexamethasone-treated rats were injected with saline or insulin and after 30 and 90 s, the liver and hindlimb skeletal muscle were removed and homogenized as described in Methods, and the extracts subjected to SDS-PAGE under reducing conditions and blotted to nitrocellulose membranes. These blots could then be analyzed using antiinsulin receptor, anti-IRS-1, and antiphosphotyrosine antibodies, while parallel extracts were assayed for PI 3-kinase activity and protein level.
Glucocorticoid-induced insulin resistance was associated with a slight increase in insulin receptor levels in muscle, but dramatically decreased IRS-1 protein levels (Fig. 1 ) . When the results of eight similar experiments were subjected to scanning densitometry, there was a 38.0±7.1% increase in insulin receptor levels in muscle of dexamethasone-treated rats in samples normalized per protein as determined by immunoblotting with an antibody to the COOH terminus of the insulin receptor (Fig. 2 A) . By contrast, the levels of IRS-1 protein in muscle detected by immunoblotting were decreased by 61.4±5.0% in rats treated with dexamethasone for 5 d (Fig. 2 A) .
After in vivo insulin stimulation, the extent of insulin receptor autophosphorylation and IRS-I phosphorylation as determined by immunoblotting with an antiphosphotyrosine antibody were similar in muscle of the dexamethasone-treated and control rats (Figs. 1 A and 2 B) . However, when the data were corrected for the change in number of insulin receptors and IRS-1 molecules, the results are divergent, with a modest decrease in the apparent stoichiometry of insulin receptor phosphorylation but a more than twofold increase in the stoichiometry of IRS-1 phosphorylation in the dexamethasonetreated rats (Fig. 2 C) . Thus, the increase in the phosphorylation ofIRS-1 protein as a result ofsteroid treatment might be of limited biological significance since the number ofIRS-1 molecules was dramatically decreased and the overall phosphorylation was slightly reduced when compared to controls (Fig. 1  A) Figure 2 . Insulin receptor and IRS-I protein and tyrosine phosphorylation levels (after in vivo insulin stimulation) in muscle of control and dexamethasone-treated rats. Scanning densitometry of autoradiograms was performed on eight experiments for insulin receptor and IRS-I concentration and six experiments for tyrosine phosphorylation levels ofboth. The data are expressed as mean±SEM. *Indicates differences statistically significant at least at P < 0.05.
phoretic mobility in IRS-I band observed after insulin stimulation because of the change in phosphorylation state, but this was not consistently observed ( Fig. 1 B) .
Effect ofdexamethasone treatment on insulin receptor and IRS-I phosphorylation in liver in rats. The effect ofdexamethasone treatment on insulin receptor and IRS-I in liver was different from that in muscle. There was no change in insulin receptor level as detected by immunoblotting in liver of animals treated with dexamethasone, whether normalized per protein or DNA (Figs. 3 C and 4 A) . Furthermore, in contrast to the decrease in IRS-I observed in muscle, immunoblotting ofliver extracts with antibodies to IRS-I revealed that the level ofIRS-I was increased by 73.0±35.3% (P < 0.05) in dexamethasone-treated rats as compared to controls (Figs. 3 B and 4 A) .
After dexamethasone treatment, changes were observed in both basal and stimulated phosphorylation of the insulin receptor and IRS-I in liver. Before insulin stimulation, basal insulin receptor phosphorylation was -36% higher in dexamethasone-treated rats than in controls, whereas after insulin stimulation the extent of phosphorylation of insulin receptor was reduced by 46.7±9.1% (P < 0.05) in treated rats compared to controls (Figs. 3 A and 4 B) . Accordingly, the tyrosine phosphorylation of IRS-1 was increased by 84±10% (P < 0.05) before insulin stimulation in dexamethasone-treated rats while the level of insulin-stimulated phosphorylation of IRS-I was reduced by 31.3±10.9% (P < 0.05) in the presence ofglucocorticoid excess (Figs. 3 A and 4 B) . When the data are expressed as a function ofthe amount ofinsulin receptor and IRS-I molecules, there was a 40-50% in the stoichiometry ofinsulin receptor and IRS-I phosphorylation in the liver of the dexamethasone-treated rats (Fig. 4 C) .
Characteristics ofinsulin-stimulated PI 3-kinase activity of liver and muscle in vivo in control and dexamethasone treated rats. To determine the impact of changes in IRS-I expression and phosphorylation on a further downstream effect, rats were injected with saline or insulin as described above, extracts of liver and hindlimb muscle were prepared and immunoprecipitated with anti-IRS-I antibodies, and the washed immunoprecipitates were assayed in vitro for PI-3 kinase activity.
A low level of basal PI-3 kinase activity was present in the anti-IRS-I immunoprecipitates from liver of control rats correspondingto a relative specific activity of0.47±0.07 pmol/ mg protein per min. After insulin stimulation there was a rapid and dramatic 25-fold increase in IRS-I associated PI-3 kinase activity (Fig. 5 A) . This is similar to magnitude to the increase in IRS-I phosphorylation that occurs after insulin stimulation. In liver ofdexamethasone-treated rats, there was a significantly higher basal level ofIRS-I-associated PI-3 kinase activity compared to control rats (specific activity = 1.47±0.15 vs 0.47±0.07 pmol/mg protein per min, P < 0.05) (Fig. 5) . However, after insulin stimulation, there was only a 1.7-fold increase in the PI 3-kinase activity in liver of dexamethasonetreated rats. Thus, when compared with controls, the levels of insulin-stimulated PI-3 kinase activity in anti-IRS-I immunoprecipitates was reduced by 79.5% after dexamethasone treatment (Fig. 5) .
In muscle, IRS-I-associated PI 3-kinase activity in the basal state was slightly reduced in dexamethasone-treated rats as compared to controls (specific activity = 1.60±0.37 vs 2.21±0.31 pmol/mg protein per min), although this difference was not statistically significant. After insulin stimulation there were a sevenfold stimulation in PI 3-kinase activity in control rats, but only a fivefold stimulation in muscle of dexamethasone-treated rats despite the lower basal level. Thus, when compared with controls, the absolute level of insulin-stimulated PI 3-kinase activity in anti-IRS-I immunoprecipitates was reduced by 41.2% in dexamethasone-treated rats (Fig. 5) .
To determine if these changes might be caused by differences in the total amount ofPI 3-kinase in tissues ofdexamethasone-treated animals, we determined the level of total enzyme protein by immunoblotting the tissue extracts with an antibody to the 85-kD subunit of PI 3-kinase. Based on immunoreactivity, the levels ofthis enzyme showed a tissue-specific regulation similar to that observed with IRS-1. PI 3-kinase protein levels decreased to 65.5±14% of control values in muscle of dexamethasone-treated rats, but increased to 125.0±9.3% ofcontrol in liver (Fig. 6 ). These changes paralleled the changes that Figure 3. Insulin-stimulated tyrosine phosphorylation in intact liver from rats treated with dexamethasone. Rats were anesthetized and the abdominal wall was incised to expose viscera. 1 antibody, there was a >50% decrease in insulin stimulated IRS-1 phosphorylation in dexamethasone-treated rats, confirming the finding with whole tissue extracts (compare Figs. 3 A and 7 A). When the same blot was subsequently incubated with antibodies directed against the 85-kD subunit of PI 3-kinase, there was little detectable immunoreactivity in the basal state in normal animals, however this was increased in steroid-treated animals (Fig. 7 B) , possibly because of the higher basal insulin levels. After insulin stimulation, a band with the expected molecular weight ofregulatory subunit ofPI 3-kinase (85 kD) was present in anti-IRS-l immunoprecipitates from liver of both groups of rats consistent with a stable association of IRS-I and PI 3-kinase. However, the amount of PI 3-kinase associated with IRS-1 was reduced -35% in dexamethasone-treated rats, suggesting less association between IRS-1 /PI 3-kinase. These data are in accordance with the reduction in PI 3-kinase activity in immunoprecipitates of anti-IRS-1 antibodies in liver of these rats. The same experiment was also done for muscle, and the results showed that after insulin stimulation the amount of immunoreactive PI 3-kinase in immunoprecipitates of anti-IRS-1 antibodies was very similar in controls and in dexamethasone-treated rats (data not shown). :0 01 _ Figure 6 . PI 3-kinase levels in liver and muscle of control and dexamethasone-treated rats. The proteins from muscle and liver were extracted and processed as described in legends to Figs. 1 and 3, and detected with anti-PI 3-kinase antibody (p85) and '251-protein A and subjected to autoradiography. The bars represent mean±SEM of five experiments for muscle and eight for liver. *Indicates differences from control at P < 0.05. Immunoblotting of tyrosyl phosphorylated proteins and PI 3-kinase in anti-IRS-I immunoprecipitates from liver of control and dexamethasone-treated rats. The protein from liver were extracted and processed as described in legend of Fig. 3 (5, 8, 9, 28) . Thus, tyrosine phosphorylation of IRS-I leads to a second early intracellular step in insulin action, an association of IRS-1 with the enzyme PI 3-kinase (8, 9) . The association probably occurs through phosphorylated YMXM motifs on IRS-1 and the SH2 domain on the 85-kD subunit ofthe PI 3-kinase (8, 9) . Insulin also increases the cellular concentration of phosphatidylinositol 3-phosphate (PI 3-P), PI(3, 4)P2, and PI(3, 4, 5 )P3, indicating that the PI 3-kinase is activated during insulin stimulation (29) (30) (31) . The phosphorylation of IRS-1 and the activation ofPI 3-kinase is decreased in cells expressing mutant insulin receptors, and the decrease correlates with defective insulin signaling, suggesting that these steps have an important role in insulin action (23, 32) . Recently, we demonstrated that in a mouse model of insulin resistance and non-insulin-dependent diabetes mellitus (the ob/ob mouse), insulin receptor, IRS-I phosphorylation, and PI 3-kinase activity are reduced in liver and muscle after insulin stimulation in vivo, pointing to a postbinding defect in insulin action in these animals (19, 33) . The role of possible alterations in PI 3-kinase in insulin resistant states has not yet been studied. In the present study, we have evaluated the role of insulin receptor and IRS-1 phosphorylation and also the association/activation of PI 3-kinase with IRS-I in liver and muscle of rats treated with dexamethasone.
Dexamethasone treatment of rats induces marked insulin resistance as evidenced by altered glucose metabolism in both peripheral tissues and liver, as well as decreased insulin-stimulated amino acid uptake in muscle, and decreased lipogenesis in adipocytes ( 10, 11, 15, 33a ). This occurs with no significant change in insulin receptor levels in liver and a small increase in muscle. Dexamethasone has been shown to stimulate the synthesis of insulin receptors in IM-9 lymphocytes (34) and in cultured rat hepatocytes ( 35 ) , and to decrease receptor degradation in 3T3 mouse fibroblasts (36) . Thus, any downregulation caused by increased circulating insulin levels in the dexamethasone-treated rats is probably offset by effects of glucocorticoids on receptor synthesis and/or degradation.
Despite the normal number of receptors in liver and the slight increase in receptors in muscle, we found -40-50% reduction in insulin receptor autophosphorylation after insulin stimulation in vivo in both tissues. In muscle this may or may not be of biological significance, since the decrease in receptor phosphorylation was offset completely by the increase in receptor number. These findings are consistent with previous studies from our laboratory ( 17) and others ( 18, 37) . The changes in IRS-I levels in dexamethasone-treated rats show a tissue-specific regulation decreasing by 61% in muscle and increasing by 73% in liver. Recently, we demonstrated that in hypoinsulinemic states of insulin resistance, such as fasting and streptozotocin-induced diabetes, there is also a tissue-specific regulation of IRS-I ( 19) , but the changes we observed after dexamethasone administration are more marked than in either of these conditions. The increase in levels of IRS-1 in liver of dexamethasone-treated rats are in contrast to the decrease in the level of IRS-I in liver, which we have observed in another hyperinsulinemic model of insulin resistance, the ob/ ob mouse ( 19) . The differences in IRS-1 levels between these dexamethasone-treated rats and the ob/ob mouse suggest that the level of IRS-I in liver is modulated not only by the hyperinsulinemia, but also by high levels of dexamethasone, and that the steroid effect dominates over the insulin effect. The dominance of glucocorticoids over insulin is somewhat surprising, since with other effects in liver, such as regulation of phosphoenolpyruvate-carboxy kinase, insulin dominates over dexamethasone (38, 39) .
In addition to the differing effects of glucocorticoids on IRS-I protein levels in liver and muscle, there is a differential effect on the stoichiometry ofphosphorylation ofIRS-1, which is reduced by 60% in liver and increased by 136% in muscle of dexamethasone-treated rats. The findings in liver are in agreement with the decrease in insulin receptor phosphorylation in kinase activity observed in that tissue, reinforcing our previous observation that IRS-I phosphorylation may depend more on insulin receptor phosphorylation and kinase activity than IRS-1 protein levels ( 19) . The finding in muscle is difficult to explain, but suggests that there can be differential coupling between insulin receptor autophosphorylation and its ability to catalyze IRS-I phosphorylation. Since the concentration of IRS-I in liver and muscle is normally similar to that of the receptor, it is possible that the increase in the ratio of insulin receptor protein to IRS-I protein in muscle ofdexamethasone- treated rats increases the efficiency of coupling between the enzyme and its substrate. Interestingly, PI 3-kinase levels also showed tissue specific regulation in the dexamethasone-treated rats which was similar but less dramatic than the glucocorticoid effect on IRS-1. The increased levels of IRS-I and PI 3-kinase protein in liver and the decreased levels in muscle in dexamethasone-treated rats correlate with the changes in basal PI 3-kinase activity in anti-IRS-I immunoprecipitates from these tissues and suggest that the levels ofthese proteins has an important role in the process ofassociation/activation in the basal state. The activation ofPI 3-kinase immunoprecipitated with anti-IRS-1 antibody after insulin stimulation was dramatically reduced in both tissues of dexamethasone-treated rats, but especially so in liver. This is in accordance with the decrease in level ofphosphorylated IRSin muscle and the reduced stoichiometry of IRS-1 phosphorylation in liver.
The differences in insulin receptor and IRS-phosphorylation and also IRS-l associated PI 3-kinase activity between liver and muscle in glucocorticoid-treated rats is interesting and may reflect a tissue specific regulation of these three steps in insulin action. Alternatively, this may reflect chronic exposure of these tissues to different levels of insulin, since liver is exposed to higher insulin levels than muscle. The reduction in these initial steps after insulin binding in liver appears to be regulatory, since similar alterations are observed in other animal models ofinsulin resistance associated with hyperinsulinemia ( 19) and in cultures of rat hepatoma cells chronically treated with insulin (Saad et al., manuscript in preparation). It is important to emphasize that in muscle, the major site of glucose disposal (40) , the decrease in PI 3-kinase activation in dexamethasone-treated rats was less than that observed in liver, suggesting that the insulin resistance in this tissue might also involve steps distal to IRS-1 phosphorylation and IRS-l-associated PI 3-kinase activity.
In summary, this study shows reduced expression and/or phosphorylation of insulin receptor and IRS-1 may lead to reduced association and activation of PI 3-kinase in vivo in liver and muscle of dexamethasone-treated rats. These data suggest that changes in these early steps in insulin signal transduction may have an important role in the insulin resistance observed in these animals.
